{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:16:44Z","timestamp":1794507404425,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Third-level Talents of the Seventh Phase of Jiangsu Province 333 Talent Plan","award":["No. 2022-3-29-061"],"award-info":[{"award-number":["No. 2022-3-29-061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Threonine and tyrosine kinase (TTK) is associated with invasion and metastasis in various tumors. However, the prognostic importance of TTK and its correlation with immune infiltration in endometrial cancer (EC) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression profile of TTK was analyzed using data from The Cancer Genome Atlas (TCGA) and the Clinical Proteome Cancer Analysis Consortium (CPTAC). TTK protein and mRNA levels were verified in EC cell lines. Receiver operating characteristic (ROC) curve analysis was used to evaluate the ability of TTK to distinguish between normal and EC tissues. K-M survival analysis was also conducted to evaluate the impact of TTK on survival outcomes. Protein\u2012protein interaction (PPI) networks associated with TTK were explored using the STRING database. Functional enrichment analysis was performed to elucidate the biological functions of TTK. TTK mRNA expression and immune infiltration correlations were examined using the Tumor Immune Estimation Resource (TIMER) and the Tumor-Immune System Interaction Database (TISIDB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TTK expression was significantly greater in EC tissues than in adjacent normal tissues. Higher TTK mRNA expression was associated with tumor metastasis and advanced TNM stage. The protein and mRNA expression of TTK was significantly greater in tumor cell lines than in normal endometrial cell lines. ROC curve analysis revealed high accuracy (94.862%), sensitivity (95.652%), and specificity (94.894%) of TTK in differentiating EC from normal tissues. K-M survival analysis demonstrated that patients with high TTK expression had worse overall survival (OS) and disease-free survival (DFS) rates. Correlation analysis revealed that TTK mRNA expression was correlated with B cells and neutrophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TTK upregulation is significantly associated with poor survival outcomes and immune infiltration in patients with EC. TTK can serve as a potential biomarker for poor prognosis and a promising immunotherapy target in EC. Further investigation of the role of TTK in EC may provide valuable insights for therapeutic interventions and personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-023-03192-2","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:02:39Z","timestamp":1704769359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Upregulation of TTK expression is associated with poor prognosis and immune infiltration in endometrial cancer patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Hongxiang","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"2","key":"3192_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","volume":"161","author":"B Gu","year":"2021","unstructured":"Gu B, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990\u20132019. Gynecol Oncol. 2021;161(2):573\u201380.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"3192_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, et al. UALCAN: a portal for facilitating Tumor Subgroup Gene expression and survival analyses. Neoplasia. 2017;19(8):649\u201358.","journal-title":"Neoplasia"},{"issue":"4","key":"3192_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","volume":"110","author":"J Lortet-Tieulent","year":"2018","unstructured":"Lortet-Tieulent J, et al. International patterns and trends in Endometrial Cancer incidence, 1978\u20132013. J Natl Cancer Inst. 2018;110(4):354\u201361.","journal-title":"J Natl Cancer Inst"},{"issue":"9470","key":"3192_CR4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(05)66431-8","volume":"365","author":"LA Brinton","year":"2005","unstructured":"Brinton LA, Lacey JV Jr., Trimble EL. Hormones and endometrial cancer\u2013new data from the million women study. Lancet. 2005;365(9470):1517\u20138.","journal-title":"Lancet"},{"issue":"1","key":"3192_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","volume":"26","author":"N Colombo","year":"2016","unstructured":"Colombo N, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2\u201330.","journal-title":"Int J Gynecol Cancer"},{"issue":"10333","key":"3192_CR6","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, et al. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328.","journal-title":"Lancet"},{"key":"3192_CR7","doi-asserted-by":"crossref","unstructured":"Rizzo A. Immune Checkpoint inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: elective affinities. J Clin Med, 2022. 11(13).","DOI":"10.3390\/jcm11133912"},{"issue":"22","key":"3192_CR8","doi-asserted-by":"publisher","first-page":"R966","DOI":"10.1016\/j.cub.2012.10.006","volume":"22","author":"P Lara-Gonzalez","year":"2012","unstructured":"Lara-Gonzalez P, Westhorpe FG, Taylor SS. The spindle assembly checkpoint. Curr Biol. 2012;22(22):R966\u201380.","journal-title":"Curr Biol"},{"issue":"4","key":"3192_CR9","first-page":"1210","volume":"15","author":"H Chen","year":"2023","unstructured":"Chen H, et al. Inhibition of apoptosis through AKT-mTOR pathway in Ovarian cancer and renal cancer. Aging. 2023;15(4):1210\u201327.","journal-title":"Aging"},{"issue":"3","key":"3192_CR10","doi-asserted-by":"publisher","first-page":"e2000174","DOI":"10.1002\/bies.202000174","volume":"43","author":"J Duro","year":"2021","unstructured":"Duro J, Nilsson J. SAC during early cell divisions: sacrificing fidelity over timely division, regulated differently across organisms: chromosome alignment and segregation are left unsupervised from the onset of development until checkpoint activity is acquired, varying from species to species. BioEssays. 2021;43(3):e2000174.","journal-title":"BioEssays"},{"issue":"37","key":"3192_CR11","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.1073\/pnas.1400892111","volume":"111","author":"F Foijer","year":"2014","unstructured":"Foijer F, et al. Chromosome instability induced by Mps1 and p53 mutation generates aggressive Lymphomas exhibiting aneuploidy-induced stress. Proc Natl Acad Sci U S A. 2014;111(37):13427\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3192_CR12","doi-asserted-by":"crossref","unstructured":"Longo LVG et al. TTK\/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for Myeloma. Haematologica, 2023.","DOI":"10.3324\/haematol.2023.282838"},{"issue":"2","key":"3192_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/1061186X.2016.1258568","volume":"25","author":"Y Xie","year":"2017","unstructured":"Xie Y, et al. Mps1\/TTK: a novel target and biomarker for cancer. J Drug Target. 2017;25(2):112\u20138.","journal-title":"J Drug Target"},{"issue":"10","key":"3192_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"21","key":"3192_CR15","doi-asserted-by":"publisher","first-page":"10148","DOI":"10.1158\/0008-5472.CAN-07-1887","volume":"67","author":"G Salvatore","year":"2007","unstructured":"Salvatore G, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007;67(21):10148\u201358.","journal-title":"Cancer Res"},{"issue":"10","key":"3192_CR16","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1093\/annonc\/mdv293","volume":"26","author":"AR Maia","year":"2015","unstructured":"Maia AR, et al. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative Breast cancer model. Ann Oncol. 2015;26(10):2180\u201392.","journal-title":"Ann Oncol"},{"issue":"14","key":"3192_CR17","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jmb.2017.05.014","volume":"429","author":"JCM Uitdehaag","year":"2017","unstructured":"Uitdehaag JCM, et al. Target Residence Time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity. J Mol Biol. 2017;429(14):2211\u201330.","journal-title":"J Mol Biol"},{"issue":"19","key":"3192_CR18","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/onc.2015.319","volume":"35","author":"A Koch","year":"2016","unstructured":"Koch A, et al. Molecular basis underlying resistance to Mps1\/TTK inhibitors. Oncogene. 2016;35(19):2518\u201328.","journal-title":"Oncogene"},{"issue":"1a","key":"3192_CR19","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68\u201377.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"3192_CR20","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1021\/pr501254j","volume":"14","author":"NJ Edwards","year":"2015","unstructured":"Edwards NJ, et al. The CPTAC Data Portal: a resource for Cancer Proteomics Research. J Proteome Res. 2015;14(6):2707\u201313.","journal-title":"J Proteome Res"},{"issue":"W1","key":"3192_CR21","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u2013w560.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"3192_CR22","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"D Szklarczyk","year":"2011","unstructured":"Szklarczyk D, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39(Database issue):D561\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"3192_CR23","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, et al. TIMER: a web server for Comprehensive Analysis of Tumor-infiltrating Immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"20","key":"3192_CR24","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132.","journal-title":"Bioinformatics"},{"key":"3192_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"issue":"17","key":"3192_CR26","doi-asserted-by":"publisher","first-page":"12670","DOI":"10.1021\/acs.jmedchem.1c00635","volume":"64","author":"J Elsner","year":"2021","unstructured":"Elsner J, et al. Structure-guided optimization provides a series of TTK protein inhibitors with Potent Antitumor Activity. J Med Chem. 2021;64(17):12670\u20139.","journal-title":"J Med Chem"},{"issue":"2","key":"3192_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1172\/JCI130435","volume":"130","author":"BC Chandler","year":"2020","unstructured":"Chandler BC, et al. TTK inhibition radiosensitizes basal-like Breast cancer through impaired homologous recombination. J Clin Invest. 2020;130(2):958\u201373.","journal-title":"J Clin Invest"},{"issue":"9","key":"3192_CR28","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/bjc.2014.460","volume":"111","author":"BP Kaistha","year":"2014","unstructured":"Kaistha BP, et al. Key role of dual specificity kinase TTK in proliferation and survival of Pancreatic cancer cells. Br J Cancer. 2014;111(9):1780\u20137.","journal-title":"Br J Cancer"},{"issue":"32","key":"3192_CR29","doi-asserted-by":"publisher","first-page":"e2119514119","DOI":"10.1073\/pnas.2119514119","volume":"119","author":"CY Chan","year":"2022","unstructured":"Chan CY, et al. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2022;119(32):e2119514119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3192_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41416-018-0081-2","volume":"118","author":"ARR Maia","year":"2018","unstructured":"Maia ARR, et al. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. Br J Cancer. 2018;118(12):1586\u201395.","journal-title":"Br J Cancer"},{"key":"3192_CR31","doi-asserted-by":"publisher","first-page":"870660","DOI":"10.3389\/fphar.2022.870660","volume":"13","author":"L Zhu","year":"2022","unstructured":"Zhu L, et al. Identification of potential biomarkers for Pan-cancer diagnosis and prognosis through the integration of large-scale Transcriptomic Data. Front Pharmacol. 2022;13:870660.","journal-title":"Front Pharmacol"},{"issue":"9","key":"3192_CR32","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.7150\/thno.22901","volume":"8","author":"X Chen","year":"2018","unstructured":"Chen X, et al. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell Lung cancer. Theranostics. 2018;8(9):2348\u201360.","journal-title":"Theranostics"},{"key":"3192_CR33","doi-asserted-by":"crossref","unstructured":"Tsai YM et al. Upregulation of Thr\/Tyr kinase increases the Cancer Progression by Neurotensin and Dihydropyrimidinase-Like 3 in Lung Cancer. Int J Mol Sci, 2020. 21(5).","DOI":"10.3390\/ijms21051640"},{"issue":"6","key":"3192_CR34","doi-asserted-by":"publisher","first-page":"e1010459","DOI":"10.1371\/journal.pcbi.1010459","volume":"19","author":"C Basanta","year":"2023","unstructured":"Basanta C, et al. Community detection in empirical kinase networks identifies new potential members of signalling pathways. PLoS Comput Biol. 2023;19(6):e1010459.","journal-title":"PLoS Comput Biol"},{"key":"3192_CR35","doi-asserted-by":"publisher","first-page":"33121","DOI":"10.1038\/srep33121","volume":"6","author":"R Miao","year":"2016","unstructured":"Miao R, et al. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of Liver cancer. Sci Rep. 2016;6:33121.","journal-title":"Sci Rep"},{"issue":"4","key":"3192_CR36","first-page":"933","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic Target Tumor Microenvironment Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Therapeutic Target Tumor Microenvironment Cancer Discov"},{"issue":"6","key":"3192_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845\u2013865e7.","journal-title":"Cancer Cell"},{"issue":"3","key":"3192_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7150\/thno.51777","volume":"11","author":"D Chen","year":"2021","unstructured":"Chen D, et al. Metabolic regulatory crosstalk between Tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016\u201330.","journal-title":"Theranostics"},{"issue":"9","key":"3192_CR39","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1021\/acs.jmedchem.8b01869","volume":"62","author":"JR Riggs","year":"2019","unstructured":"Riggs JR, et al. Design and optimization leading to an orally active TTK protein kinase inhibitor with robust single Agent Efficacy. J Med Chem. 2019;62(9):4401\u201310.","journal-title":"J Med Chem"},{"issue":"8","key":"3192_CR40","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1111\/cas.14505","volume":"111","author":"ZX Wu","year":"2020","unstructured":"Wu ZX, et al. Dual TTK\/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in Lung cancer cells. Cancer Sci. 2020;111(8):2872\u201382.","journal-title":"Cancer Sci"},{"key":"3192_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2021.01.089","volume":"550","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. TTK inhibitor promotes radiosensitivity of Liver cancer cells through p21. Biochem Biophys Res Commun. 2021;550:84\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"3192_CR42","doi-asserted-by":"publisher","first-page":"103596","DOI":"10.1016\/j.critrevonc.2022.103596","volume":"170","author":"M Santoni","year":"2022","unstructured":"Santoni M, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3192_CR43","doi-asserted-by":"crossref","unstructured":"Mollica V, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med; 2023.","DOI":"10.1007\/s10238-023-01159-1"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-03192-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:07:12Z","timestamp":1704769632000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-03192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-03192-2","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Affiliated Hospital of Nantong University Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}